MYD88 and diffuse large B-cell lymphoma: In line with this, we evaluated an additional series of 71 extranodal DLBCL samples by AS-PCR and found a prevalence of the MYD88 p.L265P mutation of 45%, in sharp contrast to the less than 10% of nodal lymphoma cases that exhibited the mutation (see S2 Table in S1 File).